Peptide Comparison

DulaglutidevsLiraglutide

Once-weekly GLP-1 receptor agonist Fc-fusion protein (Trulicity) that reduces HbA1c by 1.5–1.9%, promotes 3–4.6 kg weight loss, and demonstrated cardiovascular event reduction in the REWIND trial — available in convenient pre-filled autoinjector with no reconstitution required

FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

Dulaglutide

0.75–4.5 mg

Liraglutide

0.6–3.0 mg

Frequency

Dulaglutide

Once weekly

Liraglutide

Once daily

Administration

Dulaglutide

Subcutaneous injection

Liraglutide

Subcutaneous injection

Cycle Length

Dulaglutide

Ongoing/indefinite

Liraglutide

Ongoing/indefinite

Onset Speed

Dulaglutide

Gradual (3-4 weeks)

Liraglutide

Gradual (3-4 weeks)

Evidence Level

Dulaglutide

Strong human trials (Phase 3 or FDA approved)

Liraglutide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Dulaglutide

Liraglutide

Metabolic

Dulaglutide9%

Liraglutide9%

Weight Management

Dulaglutide8%

Liraglutide9%

Healing & Recovery

Dulaglutide8%

Liraglutide8%

Technical Data

Compound
specifications

Dulaglutide

Molecular Formula

C₂₆₄₆H₄₀₄₄N₇₀₄O₈₃₆S₁₈ (complete fusion protein homodimer)

Molecular Weight

~63 kDa (~59,670 Da per chain)

Half-Life

~5 days (terminal elimination); Tmax ~48 hours; steady state in 2–4 weeks; accumulation ratio 1.56 at 1.5 mg

Bioavailability

47–65% after subcutaneous injection (dose-dependent); apparent clearance 0.142 L/h

CAS Number

923950-08-7

Liraglutide

Molecular Formula

C₁₇₂H₂₆₅N₄₃O₅₁

Molecular Weight

3,751 Da

Half-Life

~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days

Bioavailability

~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety

CAS Number

204656-20-2

Protocols

Dosing
tiers

Dulaglutide

starting

0.75 mg subcutaneous once weekly

Once weekly

4 weeks minimum (tolerability assessment)

Initiate at 0.75 mg weekly to assess gastrointestinal tolerability. Inject in abdomen, thigh, or upper arm on the same day each week — timing can be changed as long as the last dose was at least 3 days prior. No reconstitution required; use the pre-filled autoinjector pen. If combining with insulin or sulfonylureas, consider reducing their dose to minimize hypoglycemia.

standard

1.5 mg subcutaneous once weekly

Once weekly

Ongoing chronic therapy

Standard maintenance dose for most type 2 diabetes patients. Increase from 0.75 mg after at least 4 weeks if additional glycemic control is needed. This dose provides HbA1c reduction of approximately 1.5% and weight loss of 3.0 kg. The ready-to-use autoinjector pen simplifies administration. No dose adjustment needed for renal or hepatic impairment.

advanced

3.0–4.5 mg subcutaneous once weekly

Once weekly

Ongoing chronic therapy

Higher doses approved in 2020 for patients requiring additional glycemic control. AWARD-11 demonstrated 4.5 mg superiority over 1.5 mg: HbA1c -1.77% vs -1.54% and weight loss -4.6 kg vs -3.0 kg. Titrate from 1.5 mg to 3.0 mg and then to 4.5 mg at minimum 4-week intervals. GI side effects are dose-dependent but generally tolerable with gradual escalation.

Liraglutide

starting

0.6 mg subcutaneous once daily

Once daily

1 week (tolerability assessment)

Begin at 0.6 mg daily for the first week to assess gastrointestinal tolerability before dose escalation. This starting dose is sub-therapeutic for both diabetes and obesity indications. Inject in abdomen, thigh, or upper arm at any time of day regardless of meals. Rotate injection sites. GI side effects (nausea) are most common during the initial titration period.

standard

1.2–1.8 mg subcutaneous once daily

Once daily

Ongoing chronic therapy

Standard therapeutic dose range for type 2 diabetes (Victoza). Escalate from 0.6 mg to 1.2 mg at week 2 and optionally to 1.8 mg at week 3 for additional glycemic benefit. Maximum diabetes dose is 1.8 mg/day. No dose adjustment needed for renal or hepatic impairment. If combining with sulfonylureas, reduce sulfonylurea dose by 50% to minimize hypoglycemia. Store in-use pen at room temperature or refrigerated for up to 30 days.

advanced

3.0 mg subcutaneous once daily

Once daily

Ongoing chronic therapy with 16-week efficacy assessment

Obesity dose (Saxenda) reached through weekly 0.6 mg increments: 0.6→1.2→1.8→2.4→3.0 mg over 5 weeks. Evaluate response at 16 weeks — if <4% body weight loss, consider discontinuation as unlikely to achieve meaningful benefit. Must be combined with reduced-calorie diet and increased physical activity. Approved for BMI ≥30 or BMI ≥27 with weight-related comorbidities. Do not use simultaneously with Victoza or any other GLP-1 RA.

Applications

Best
suited for

Dulaglutide

Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control

Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection

Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction

Dulaglutide is particularly well-suited for individuals focused on overweight or obese t2dm patients requiring both weight loss and hba1c reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Pediatric patients aged 10–17 with type 2 diabetes (approved indication)

Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Liraglutide

Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management

Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy

Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy

Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile

Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Dulaglutide

Common

Nausea
Diarrhea and abdominal pain
Vomiting
Decreased appetite

Uncommon

Injection site reactions and fatigue

Serious

Acute pancreatitis
Gallbladder disease

Liraglutide

Common

Nausea
Diarrhea
Vomiting
Decreased appetite and headache

Uncommon

Injection site reactions

Serious

Acute pancreatitis
Gallbladder disease

Research Status

Safety
& evidence

Dulaglutide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Dulaglutide is an FDA-approved GLP-1 receptor agonist carrying a black box warning for thyroid C-cell tumor risk, based on rodent data showing increased medullary thyroid cancer (MTC) in rat models. This risk is contraindicated in patients with personal or family history of MTC or multiple endocrine neoplasia type 2. Nausea occurs in 20-40% of patients, particularly dose-dependent and most severe at initiation; gastrointestinal side effects (vomiting, diarrhea) are common. Pancreatitis has been reported in 0.1-0.2% of patients—discontinue immediately if severe abdominal pain develops. Rapid weight loss can trigger gallstone formation. Dehydration risk is significant, especially with concurrent SGLT2 inhibitors. Injection site reactions are mild but frequent.

Contraindications

xPersonal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor data
xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
xKnown serious hypersensitivity to dulaglutide or any excipient
xType 1 diabetes mellitus or diabetic ketoacidosis (not indicated)

Liraglutide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.

Contraindications

xPersonal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings
xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
xKnown hypersensitivity to liraglutide or any excipients
xPregnancy (Saxenda indication) — contraindicated; effective contraception required

Decision Guide

Which is
right for you?

Choose Dulaglutide if...

Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
Pediatric patients aged 10–17 with type 2 diabetes (approved indication)

Choose Liraglutide if...

Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile

Full Dulaglutide Profile Full Liraglutide Profile

Peptide Database

Quickcomparison

Benefitratings

Compoundspecifications

Dosingtiers

Bestsuited for

Sideeffects

Safety& evidence

Which isright for you?

Quick
comparison

Benefit
ratings

Compound
specifications

Dosing
tiers

Best
suited for

Side
effects

Safety
& evidence

Which is
right for you?